Amgen's experimental weight loss injection, MariTide, showed up to 20% weight loss in patients without diabetes and 17% in ...

MariTide is being studied for the treatment of obesity and Type 2 diabetes and demonstrated weight loss at 52 weeks.

In cases involving unpredictable factors, such as most chemical reactions, pharmaceutical activity, and physiological ...

A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.

Whoever says the Food and Drug Administration is too cozy with Big Pharma isn’t paying attention to the bonanza of new ...

RBC Capital analyst Gregory Renza lowered the firm’s price target on Amgen (AMGN) to $330 from $360 and keeps an Outperform rating on the ...

Stocks shrug off a new Trump tariff threat as the president-elect vows sweeping levies on the biggest U.S. trading partners.

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...

A new experimental weight loss drug from Amgen — the first in a growing group of drugs aimed at once-a-month injections instead of once a week — helped patients lose up to 20% of their weight in one ...

Goldman Sachs analyst Salveen Richter has maintained their bullish stance on AMGN stock, giving a Buy rating yesterday.Don't Miss our Black ...

That increased convenience will have to be accompanied by weight loss that is at least as effective as its rivals, and Amgen ...